Calamos Advisors LLC Buys 117,358 Shares of Medtronic PLC $MDT

Calamos Advisors LLC grew its stake in Medtronic PLC (NYSE:MDT) by 27.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 538,018 shares of the medical technology company’s stock after acquiring an additional 117,358 shares during the period. Calamos Advisors LLC’s holdings in Medtronic were worth $51,241,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also modified their holdings of MDT. 1248 Management LLC bought a new position in Medtronic in the 1st quarter valued at about $26,000. Delos Wealth Advisors LLC acquired a new position in shares of Medtronic in the second quarter valued at approximately $27,000. Twin Tree Management LP bought a new position in shares of Medtronic during the first quarter worth approximately $29,000. Tripletail Wealth Management LLC bought a new position in shares of Medtronic during the third quarter worth approximately $34,000. Finally, GFG Capital LLC acquired a new stake in Medtronic during the 2nd quarter worth approximately $36,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Trading Up 0.5%

MDT opened at $96.68 on Wednesday. The stock has a market capitalization of $123.94 billion, a price-to-earnings ratio of 26.06, a P/E/G ratio of 2.53 and a beta of 0.71. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. Medtronic PLC has a twelve month low of $79.38 and a twelve month high of $106.33. The company has a 50-day simple moving average of $97.56 and a 200 day simple moving average of $93.92.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is currently 76.55%.

Wall Street Analysts Forecast Growth

MDT has been the topic of a number of research reports. Barclays upped their price objective on Medtronic from $109.00 to $111.00 and gave the company an “overweight” rating in a report on Thursday, November 20th. JPMorgan Chase & Co. upped their price target on shares of Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Leerink Partners set a $120.00 price objective on shares of Medtronic and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Cowen reissued a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Finally, Stifel Nicolaus increased their target price on shares of Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a research report on Thursday, October 9th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $109.94.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).